Lineage Cell Therapeutics, Inc. Repayments of Long-term Capital Lease Obligations
Lineage Cell Therapeutics, Inc. (LCTX) reported Repayments of Long-term Capital Lease Obligations of $248.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermCapitalLeaseObligations · last filed 2019-03-14
- Lineage Cell Therapeutics, Inc. repayments of long-term capital lease obligations for the quarter ending 2018-12-31 was $93.00K, a 46.24% decline year-over-year.
- Lineage Cell Therapeutics, Inc. repayments of long-term capital lease obligations for the quarter ending 2018-09-30 was $4.00K.
- Lineage Cell Therapeutics, Inc. repayments of long-term capital lease obligations for the quarter ending 2018-06-30 was $54.00K.
- Lineage Cell Therapeutics, Inc. repayments of long-term capital lease obligations for the quarter ending 2018-03-31 was $97.00K, a 212.90% increase year-over-year.
- Lineage Cell Therapeutics, Inc. repayments of long-term capital lease obligations for fiscal 2018 was $248.00K, a 21.57% increase from fiscal 2017.
- Lineage Cell Therapeutics, Inc. repayments of long-term capital lease obligations for fiscal 2017 was $204.00K, a 40.69% increase from fiscal 2016.
- Lineage Cell Therapeutics, Inc. repayments of long-term capital lease obligations for fiscal 2016 was $145.00K, a 145.76% increase from fiscal 2015.
- Lineage Cell Therapeutics, Inc. repayments of long-term capital lease obligations for fiscal 2015 was $59.00K, a 126.92% increase from fiscal 2014.
| Period end | Repayments of Long-term Capital Lease Obligations 3 month | Repayments of Long-term Capital Lease Obligations 6 month | Repayments of Long-term Capital Lease Obligations 9 month | Repayments of Long-term Capital Lease Obligations 12 month |
|---|---|---|---|---|
| 2018-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $97.00K derived: sum of 2 quarters · filed 2019-03-14 | $151.00K derived: sum of 3 quarters · filed 2019-03-14 | $248.00K 10-K · filed 2019-03-14 |
| 2018-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $58.00K derived: sum of 2 quarters · filed 2018-11-08 | $155.00K 10-Q · filed 2018-11-08 | $328.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $151.00K 10-Q · filed 2018-08-02 | $324.00K derived: sum of 3 quarters · filed 2019-03-14 | $324.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-03-31 | $97.00K 10-Q · filed 2018-05-10 | $270.00K derived: sum of 2 quarters · filed 2019-03-14 | $270.00K derived: sum of 3 quarters · filed 2019-03-14 | $270.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-12-31 | $173.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $173.00K derived: sum of 2 quarters · filed 2019-03-14 | $173.00K derived: sum of 3 quarters · filed 2019-03-14 | $204.00K 10-K · filed 2019-03-14 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $31.00K 10-Q · filed 2018-11-08 | $72.00K derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $31.00K 10-Q · filed 2018-08-02 | $72.00K derived: sum of 3 quarters · filed 2018-08-02 | $102.00K derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | $31.00K 10-Q · filed 2018-05-10 | $72.00K derived: sum of 2 quarters · filed 2018-05-10 | $102.00K derived: sum of 3 quarters · filed 2018-05-10 | $159.00K derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $71.00K derived: sum of 2 quarters · filed 2018-03-15 | $128.00K derived: sum of 3 quarters · filed 2018-03-15 | $145.00K 10-K · filed 2018-03-15 |
| 2016-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $87.00K derived: sum of 2 quarters · filed 2017-11-09 | $104.00K 10-Q · filed 2017-11-09 | $132.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $74.00K 10-Q · filed 2017-08-09 | $102.00K derived: sum of 3 quarters · filed 2018-03-15 | |
| 2016-03-31 | $17.00K 10-Q · filed 2017-05-10 | $45.00K derived: sum of 2 quarters · filed 2018-03-15 | ||
| 2015-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $59.00K 10-K · filed 2018-03-15 | ||
| 2015-09-30 | $31.00K 10-Q · filed 2016-11-04 | |||
| 2014-12-31 | $26.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |